LIEE exhibits significant anti-osteoporotic effects through a multi-targeted mechanism involving modulation of ER/OPG/RANKL signalling, suppression of inflammation and oxidative stress, and regulation of key molecular targets. These outcomes propose that LIEE could help as a capable phytotherapeutic candidate for the management of postmenopausal osteoporosis and warrant more clinical exploration.

1 day ago

Preclinical • Journal

EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • mTOR (Mechanistic target of rapamycin kinase) • IL6 (Interleukin 6) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • MMP9 (Matrix metallopeptidase 9) • IL1B (Interleukin 1, beta) • CAT (Catalase) • TNFRSF11B (Tumor necrosis factor receptor superfamily member 11B) • BGLAP (Bone Gamma-Carboxyglutamate Protein)

EGFR expression

Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset. (PubMed, Int J Urol)

Using a large-scale Japanese genomic panel dataset, we characterized the molecular alterations associated with S/DD. S/DD frequently exhibits low Nectin-4 expression and basal-like molecular features, which may have implications for treatment selection and inform future therapeutic strategies.

2 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • ARID1A (AT-rich interaction domain 1A) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • KDM6A (Lysine Demethylase 6A) • FGF4 (Fibroblast growth factor 4) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • GATA3 (GATA binding protein 3) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)

PD-L1 expression • TP53 mutation • EGFR expression • ARID1A mutation • FGFR3 mutation • RB1 mutation

Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors. (PubMed, JCO Precis Oncol)

Integrated profiling of TETs reveals distinct genomic, transcriptomic, and immune features across subtypes of TETs and identifies potentially actionable therapeutic targets that may inform future treatment strategies.

2 days ago

Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • MTAP (Methylthioadenosine Phosphorylase) • MSLN (Mesothelin) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)

PD-L1 expression • TP53 mutation • TMB-H • MSI-H/dMMR • PD-L1 overexpression • HER-2 overexpression • EGFR expression • TMB-L • CDKN2A deletion

MI Tumor Seek™

Khellin-Derived Benzofuran-Pyrazoline Hybrids as Kinase-Targeted Anticancer Agents. (PubMed, ACS Omega)

Molecular docking studies were performed on representative active compounds to rationalize observed biological activity and characterize key interactions within the ATP-binding sites of EGFR and B-RAF kinases. Collectively, these findings identify khellin-derived benzofuran-pyrazoline hybrid systems as promising candidates for targeting kinases and as potential anticancer agents, providing a rational basis for further structural optimization and mechanistic investigation.

2 days ago

Journal

EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)

EGFR expression

PRAD2: Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)

P2, N=39, Not yet recruiting, Anhui Provincial Cancer Hospital

6 days ago

New P2 trial

EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)

EGFR expression

Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)

T-cell Receptor (TCR) targeting with Multivalent T-cell Engagers. (PubMed, bioRxiv)

Although the initiation of cytotoxicity was kinetically slower than the αCD3 scFv counterpart, αTCR VHH CSANs achieved comparable end point cytotoxicity across multiple antigen densities, as well as in 3D tumor spheroids. Through this study we demonstrate the applicability of nanobodies as T-cell targeting domains, enhanced specificity and safety of moderate affinity T-cells binders and the diversification of T-cell targeting epitopes without compromising the efficacy of TCEs.

6 days ago

Journal

EGFR (Epidermal growth factor receptor)

EGFR expression • FOLH1 expression

Gene Expression Profiling of EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, and TP53 in Cell-Free RNA From Exhaled Breath Condensate: Diagnostic, Prognostic, and Therapeutic Implications in Advanced Lung Adenocarcinoma. (PubMed, Cancer Rep (Hoboken))

EBC-based cfRNA profiling provides a feasible, non-invasive approach for molecular characterization of advanced lung adenocarcinoma. Among the genes examined, PIK3CA showed the strongest diagnostic signal, FGFR2 demonstrated prognostic significance, and EGFR showed the clearest cross-sample concordance and treatment-associated relevance. Larger independent validation studies are required before clinical implementation.

7 days ago

Journal

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • SMAD4 (SMAD family member 4) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase)

EGFR expression

Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer. (PubMed, Br J Cancer)

High VEGFA is associated with aggressive biology and inferior outcomes, correlating with shorter PFS for first/second-generation EGFR-TKIs but not for osimertinib.

9 days ago

Clinical data • Journal • Tumor mutational burden

TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • KDR (Kinase insert domain receptor)

TP53 mutation • EGFR mutation • TMB-H • EGFR expression

Tagrisso (osimertinib)

A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)

P2/3, N=706, Recruiting, Shanghai Henlius Biotech | Enrolling by invitation --> Recruiting

9 days ago

Enrollment status

EGFR (Epidermal growth factor receptor)

PD-L1 expression • EGFR expression

docetaxel • pimurutamab (HLX07) • HLX43

EGFR-008-001: Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)

P1, N=130, Active, not recruiting, Janux Therapeutics | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Oct 2026 | Trial primary completion date: Jan 2026 --> Jul 2026

9 days ago

Enrollment closed • Trial completion date • Trial primary completion date • First-in-human

EGFR expression

JANX008

Expression of NF-κB, EGFR, and HER3 in castration-resistant prostate adenocarcinoma: a clinical and molecular study of 88 Moroccan patients (PubMed, Pan Afr Med J)

Nuclear activation of NF-κB and HER3, along with EGFR overexpression, plays a critical role in hormonal escape. These molecules represent promising therapeutic targets and prognostic biomarkers for high-risk PCa management in Morocco.

9 days ago

Retrospective data • Journal

EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1)

EGFR expression

Impact of Genetic and Molecular Alterations on Clinical Outcomes in Sinonasal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. (PubMed, Int Forum Allergy Rhinol)

Molecular profiling has prognostic value in SNSCC. EGFR and TP53 alterations were associated with poorer outcomes, whereas Foxp3 expression was associated with more favorable survival, supporting further biomarker-integrated risk stratification in SNSCC.

9 days ago

Clinical data • Retrospective data • Review • Journal • PD(L)-1 Biomarker • IO biomarker

EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • KMT2D (Lysine Methyltransferase 2D) • SOX2 • BAX (BCL2-associated X protein) • FOXP3 (Forkhead Box P3) • AFF2 (AF4/FMR2 family member 2)

PD-L1 expression • TP53 mutation • EGFR mutation • EGFR expression